Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 13.6% from a year ago
Other current liabilities stood at $5.49M at the end of Q1 FY2026, down 13.6% from a year earlier and down 21.0% from the prior quarter. Over 3 fiscal years it compounded at +19.8% a year.
Context
- Other current liabilities amounted to 2.2% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -13.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.95M USD
- Year-over-year change
- -47.8%
- 4-year CAGR
- +18.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.95M | -47.8% |
| FY2024 | 2024-12-31 | 13.31M | -28.1% |
| FY2023 | 2023-12-31 | 18.5M | +358.1% |
| FY2022 | 2022-12-31 | 4.04M | +12.9% |
| FY2021 | 2021-12-31 | 3.58M | — |
Other Current Liabilities vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -13.6% is the 8th highest of 10, against a peer median of +26.8%.
- Other current liabilities amounts to 2.2% of total assets for ARCT, versus a peer median of 6.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $132.45M USD | -6.7% | -37.8% | 12.7% | |
| Mar 2026 | €50.99M EUR | +68.8% | -39.5% | 13.7% | |
| Mar 2026 | $50.13M USD | +186.4% | +113.3% | 4.9% | |
| Mar 2026 | $27.02M USD | +70.3% | +34.0% | 54.3% | |
| Mar 2026 | $23.29M USD | — | +31.3% | 8.7% | |
| Mar 2026 | €10.66M EUR | +1.8% | -13.4% | 10.7% | |
| Mar 2026 | $5.49M USD | -13.6% | +19.8% | 2.2% | |
| Mar 2026 | $5.24M USD | +26.8% | +7.1% | 1.8% | |
| Mar 2026 | $541K USD | +27.0% | +2.1% | 0.3% | |
| Mar 2026 | $245K USD | -95.9% | -37.7% | 0.1% | |
| Mar 2026 | $0 USD | -100.0% | -14.3% | 0.0% | |
| Peer median (excluding ARCT) | — | +26.8% | -5.6% | 6.8% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 370.49M | 391.88M | 292.01M | 237.03M | 230.91M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 3.37M | 2.76M | 32.06M | 3.97M | 5.56M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 8.69M | 55M | 64.98M | 4.97M |
| Total Current Assets | 378.96M | 403.33M | 386.59M | 305.98M | 241.45M |
| Property, Plant & Equipment (Net) | 11.26M | 44.96M | 40.93M | 36.21M | 27.82M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 515K | 0 | 1.89M | 0 | 1.89M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.08M | 2.09M | 0 | 1.89M | 0 |
| Total Non-current Assets | 13.85M | 47.05M | 42.81M | 38.09M | 29.7M |
| Total Assets | 392.81M | 450.39M | 429.4M | 344.07M | 271.15M |
| Account Payables | 10.06M | 7.45M | 5.28M | 7.19M | 4.24M |
| Short-term Debt | 22.47M | 60.66M | 0 | 0 | 0 |
| Tax Payables | 0 | 1.3M | 641K | 0 | 0 |
| Deferred Revenue | 43.48M | 36.12M | 47.34M | 21.94M | 8.25M |
| Other Current Liabilities | 3.58M | 4.04M | 18.5M | 13.31M | 6.95M |
| Total Current Liabilities | 99.54M | 126.98M | 81.99M | 65.49M | 36.38M |
| Long-term Debt | 40.63M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 20.07M | 42.5M | 12.6M | 0 |
| Other Non-current Liabilities | 19.93M | 2.8M | 497K | 0 | 0 |
| Total Non-current Liabilities | 65.07M | 53.09M | 68.9M | 37.6M | 20.78M |
| Total Liabilities | 164.6M | 180.08M | 150.89M | 103.09M | 57.16M |
| Common Stock | 26K | 27K | 27K | 27K | 28K |
| Retained Earnings | (347.49M) | (338.14M) | (367.87M) | (448.81M) | (514.59M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 228.21M | 270.31M | 278.51M | 240.98M | 213.99M |
| Total Debt | 69.15M | 94.76M | 30.22M | 28.55M | 25M |
| Net Debt | (301.35M) | (297.13M) | (261.79M) | (208.48M) | (205.91M) |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.